Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer

To discover alternative treatments to transcriptionally active ESR1 gene fusions (ESR1-TAF), a mass spectrometry-based kinase inhibitor pulldown assay was deployed to identify druggable kinases that are upregulated by diverse ESR1-TAFs.